Skip to main content
Clinical Trials/NCT02389491
NCT02389491CompletedNot Applicable

Effect of a High Density Formula on Growth and Safety in Early Postoperative Infants With Congenital Heart Disease Duration of Cardiac Intensive Care Unit(CCU)Stay: a Randomized Clinical Trial

Children's Hospital of Fudan University0 sites64 target enrollmentStarted: March 1, 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
64
Primary Endpoint
weight gain at the 7th day (g)

Study Overview

Brief Summary

The purpose of this study is to explore the effects of high density formula in early postoperative infants with congenital heart disease and to assess its safety.

Detailed Description

The number of infants born with CHD increases every year and most CHD infants are suffered with malnutrition.Recent studies have shown that increasing energy intake in CHD infants can improve their nutrition status.But there are no high qualified evidences supporting that high density formula can promote infants' nutrition status and ensure its safety. The hypothesis of the current study is that high density formula intake can increase infants'weight and it's safe.

The current study adopts randomized,controlled intervention trial, gives high density formula(Infatrini,100kcal/100ml)to CHD infants in intervention group and normal density formula(Neocate,67kcal/100ml)in control group. Intervention begins when infants start enteral nutrition after operation and continues for 7days.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
1 Day to 12 Months (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •diagnosis of congenital heart disease from symptoms, signs, ultrasonic and imaging examination
  • •aged from 1 day to 12 months
  • •accept extracorporeal circulation open-heart surgery
  • •family members voluntarily participate in this study

Exclusion Criteria

  • •patients have other diseases which cause nutrition disorders, such as gastrointestinal malformation, preoperative gastroesophageal reflux, genetic diseases related to the growth restriction
  • •accept total parenteral nutrition
  • •predicted the length of CCU stay is less than five days
  • •patients have abdominal distention, diarrhea, vomiting

Arms & Interventions

normal density formula (Neocate)

Active Comparator

In control group,infants intake normal density formula (Neocate,67kcal/100ml) when starting enteral nutrition after operation and continue for 7days

Intervention: normal density formula (Necocate) (Dietary Supplement)

high density formula (Infatrini)

Experimental

In the intervention group,infants intake high density formula (Infatrini, 100kcal/100ml) when starting enteral nutrition after operation and continue for 7days

Intervention: high density formula(Infatrini) (Dietary Supplement)

Outcomes

Primary Outcomes

weight gain at the 7th day (g)

Time Frame: from the first day starting enteric feeding to the 7th days

the 7th day body weight minus baseline body weight

the number of participants with feeding intolerance

Time Frame: from the first day starting enteric feeding to the 7th day

Feeding intolerance means participants have gastric retention, vomiting, diarrhea ect. lead to enteric feeding was stopped.

Secondary Outcomes

  • the number of participants with poor wound healing(participants will be followed for the duration of hospital stay, an expected average of 4 weeks)
  • Duration of mechanical ventilation(participants will be followed for the duration of hospital stay, an expected average of 4 weeks)
  • length of Cardiac Intensive Care Unit(CCU) stay(participants will be followed for the duration of hospital stay, an expected average of 4 weeks)
  • the number of participants with necrotizing enterocolitis(participants will be followed for the duration of hospital stay, an expected average of 4 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Effect of a High Density Formula on Growth... | Clinical Trial